Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ehninger

Showing results (291-300 of 317) with videos related to

Pageof 32
Sort By:
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Annals of Hematology|June 24, 2016
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physiciansA Kaifie, S Isfort, N Gattermann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)A Thiel, J Schetelig, W Pönisch, et al.
Blood|June 20, 1998
Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemiaH Wandt, M Frank, G Ehninger, et al.
Bone Marrow Transplantation|August 6, 2003
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)A R Zander, N Kröger, M Schleuning, et al.
Bone Marrow Transplantation|June 11, 2003
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factorH G Sayer, M Kröger, J Beyer, et al.
Annals of Hematology|September 14, 2000
Transplant activities in Germany in 1998--a survey facilitated by the National Registry for Hemopoietic Stem Cell TransplantationH D Ottinger, C Müller, N Schmitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study GroupJ Schetelig, C Thiede, M Bornhauser, et al.
Leukemia|November 28, 2006
HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemiaA-L Herr, M Labopin, D Blaise, et al.
Journal of Hematology & Oncology|March 6, 2016
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registryA Kaifie, M Kirschner, D Wolf, et al.
Pageof 32

Showing results (291-300 of 317) with videos related to

Sort By:
Pageof 32
Leukemia|February 23, 2011
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemiaC Craddock, M Labopin, S Pillai, et al.
Annals of Hematology|June 24, 2016
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physiciansA Kaifie, S Isfort, N Gattermann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL)A Thiel, J Schetelig, W Pönisch, et al.
Blood|June 20, 1998
Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemiaH Wandt, M Frank, G Ehninger, et al.
Bone Marrow Transplantation|August 6, 2003
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)A R Zander, N Kröger, M Schleuning, et al.
Bone Marrow Transplantation|June 11, 2003
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factorH G Sayer, M Kröger, J Beyer, et al.
Annals of Hematology|September 14, 2000
Transplant activities in Germany in 1998--a survey facilitated by the National Registry for Hemopoietic Stem Cell TransplantationH D Ottinger, C Müller, N Schmitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study GroupJ Schetelig, C Thiede, M Bornhauser, et al.
Leukemia|November 28, 2006
HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemiaA-L Herr, M Labopin, D Blaise, et al.
Journal of Hematology & Oncology|March 6, 2016
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registryA Kaifie, M Kirschner, D Wolf, et al.
Pageof 32